Literature DB >> 9600288

Recent trends in diagnosis and treatment of Clostridium difficile in a tertiary care facility.

S A Butterworth1, E Koppert, A Clarke, B Wiggs, J K MacFarlane.   

Abstract

BACKGROUND: With the prevalence of antibiotic use, the diagnosis and management of Clostridium difficile disease requires assessment.
METHODS: In a retrospective review, patients with a positive culture, toxin, or both during 1 year were identified. Recent literature was reviewed. Results of culture and toxin, prior antibiotic use, antibiotic treatment history and cost were analyzed.
RESULTS: Of 592 patients tested, 101 were positive; 96 of 101 were available for review. Of those positive tested for both, 45% were positive for toxin and culture. Sixty-two of 96 were treated with antibiotics; metronidazole was used in 90%. Ten of 62 antibiotic treatments were changed (mean 3 days). Ten days of metronidazole is 1/200th the cost of vancomycin.
CONCLUSIONS: In 55% of the positive cases in which culture and toxin were obtained, one test was negative. As metronidazole's efficacy and cost compares favorably with vancomycin, metronidazole is the drug of choice. Any changes made to antibiotic regimens occurred prior to the 6 days recommended in the literature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600288     DOI: 10.1016/S0002-9610(98)00058-0

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Pseudomembranous Colitis Caused by C. difficile.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-06

Review 2.  The economic impact of Clostridium difficile infection: a systematic review.

Authors:  Natasha Nanwa; Tetyana Kendzerska; Murray Krahn; Jeffrey C Kwong; Nick Daneman; William Witteman; Nicole Mittmann; Suzanne M Cadarette; Laura Rosella; Beate Sander
Journal:  Am J Gastroenterol       Date:  2015-04-07       Impact factor: 10.864

Review 3.  A review of the economics of treating Clostridium difficile infection.

Authors:  Kari A Mergenhagen; Amy L Wojciechowski; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

4.  Cost analysis of hospitalized Clostridium difficile-associated diarrhea (CDAD).

Authors:  Claudia Hübner; Nils-Olaf Hübner; Michaela Muhr; Franziska Claus; Henning Leesch; Axel Kramer; Steffen Flessa
Journal:  GMS Hyg Infect Control       Date:  2015-10-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.